Dr Sarah Walsh s.walsh@rgu.ac.uk
Research Fellow
A novel G protein-coupled receptor target for metabolic syndrome
People Involved
Project Description
Metabolic syndrome is the medical term for a group of risk factors that increase the likelihood of developing heart disease, diabetes, and stroke. The risk factors for metabolic syndrome include high blood pressure, high blood sugar (insulin resistance), excess body fat and abnormal cholesterol: obesity is a key driving force. Metabolic syndrome is a global health problem and the associated wider costs to the NHS are estimated to reach over 50 billion/year by 2050. Given the prevalence, complexity and associated costs of metabolic syndrome, in addition to preventative approaches, understanding key regulators and uncovering new drug targets is essential. G protein coupled receptors are a family of proteins on the surface of cells that regulate numerous functions throughout the body and are the targets for >30% of approved drugs. Our lab is interested in one particular G protein-coupled receptor, namely GPR75, which we have seen is increased with diabetes, and that GPR75 deficiency is associated with lower body weight and fat mass. We intend to uncover the role of GPR75 in metabolic syndrome by investigating its functional significance in obesity-induced diabetes and high blood pressure. We believe that the proposed research, which provides an exciting opportunity to bring together the expertise of researchers from the Aberdeen Cardiovascular and Diabetes Centre and Robert Gordon University, will highlight GPR75 is a novel drug target for metabolic syndrome.
A project lead by University of Aberdeen
Status | Project Complete |
---|---|
Funder(s) | Tenovus Scotland |
Value | £1,990.00 |
Project Dates | Sep 1, 2020 - Feb 28, 2022 |
You might also like
sFRPs as a novel modulator of diastolic heart failure Oct 1, 2017 - Dec 31, 2021
Following a heart attack, or because of persistently high blood pressure the heart is damaged and has to work harder to circulate blood around the body. This condition is known as heart failure. In the UK alone, 500,000 people have heart failure re...
Read More about sFRPs as a novel modulator of diastolic heart failure.
Exploring the relationship between age-related zinc deficiency and obesity and the extent of myocardial damage following acute myocardial infarction Oct 1, 2018 - Jan 1, 2021
Zinc (Zn 2+) is a metal found in trace amounts in the body and plays an essential role in maintaining the healthy functioning of most organs, including the heart. The body does not store zinc in large quantities and so replenishment of Zn 2+ through...
Read More about Exploring the relationship between age-related zinc deficiency and obesity and the extent of myocardial damage following acute myocardial infarction.
Protective effects of cannabidiol in doxorubicin induced cardiotoxicity Oct 1, 2018 - Dec 31, 2019
Protective effects of cannabidiol in combined chemotherapy induced cardiotoxicity Jul 8, 2019 - Sep 1, 2019
Doxorubicin, an anthracycline, is one of the most effective and commonly used drugs for the treatment of cancer. This anthracycline is used both alone and in combination with other chemotherapeutic agents such as taxanes e.g. paclitaxel. Despite its...
Read More about Protective effects of cannabidiol in combined chemotherapy induced cardiotoxicity.
Bioactivity of compounds derived from Amaryllicaea (Daffodil) Feb 1, 2021 - Jul 31, 2022
Heart Failure (HF) is a long-term complication of cardiovascular (high blood pressure and heart attack) and cardiovascular-related (obesity and metabolic syndrome) disorders and of drug-induced cardiotoxicity. HF is characterised by thickening (hype...
Read More about Bioactivity of compounds derived from Amaryllicaea (Daffodil).